PT  - JOURNAL ARTICLE
AU  - Gene A. Schreck
AU  - Ryan D. Niederkohr, MD
TI  - <sup>153</sup>Sm-EDTMP Appears to Accumulate Only Trivially Within Peritoneal Ascites
AID  - 10.2967/jnmt.111.097220
DP  - 2012 Mar 01
TA  - Journal of Nuclear Medicine Technology
PG  - 50--51
VI  - 40
IP  - 1
4099  - http://tech.snmjournals.org/content/40/1/50.short
4100  - http://tech.snmjournals.org/content/40/1/50.full
SO  - J. Nucl. Med. Technol.2012 Mar 01; 40
AB  - 153Sm-lexidronam (EDTMP) is a therapeutic radiopharmaceutical used for palliation of pain resulting from osseous metastatic disease. Methods: We recently treated with 153Sm-EDTMP a patient who had extensive osseous metastases and malignant ascites requiring intermittent drainage from an indwelling catheter. Because we could find no useful data regarding quantification of accumulation of this agent within ascites, we opted to assay the fluid after treatment. Results: The measured ratio of 153Sm-EDTMP activity in peritoneal fluid (1.71 L) relative to injected dose was 0.01% (i.e., trivially above background level). Conclusion: To our knowledge, this represents the first published measurement of 153Sm-EDTMP accumulation within peritoneal fluid. This information may be useful to the nuclear medicine community since malignant ascites is not uncommon in patients with widely metastatic carcinoma and such patients may be referred for 153Sm-EDTMP therapy.